



Pandemics-Born Revolution in the Preclinical and Clinical Trials of Microbial Vaccines

Guest Editors:

Dr. Maria G. Isaguliantz

Prof. Dr. Felicity Jane Burt

Dr. Ilya Gordeychuk

Message from the Guest Editors

This issue is welcoming submissions of experimental papers, short communications, reviews and activity reports focusing on the above problems. We specifically welcome submissions which consider the impact of SARS-CoV-2 pandemics on:

Deadline for manuscript
submissions:
closed (31 August 2023)

- Development of plug and play platforms approach
- Future vaccine discovery/development; harnessing the current momentum for vaccine development to create new vaccine platforms
- Novel vaccines/technologies for accommodating emerging SARS-CoV-2 variants
- Novel vaccines/technologies against other common and emerging (re-emerging) pathogens
- Development of animal models to test vaccine efficacy
- Vaccine manufacture and upscale in the future
- Formulations that aid the stability of vaccines facilitating distribution to less accessible and low resource countries





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)